About Glomus Tumor
Head and neck paragangliomas (also historically termed glomus tumours or chemodectomas) are rare, hypervascular neuroendocrine tumours arising from paraganglia associated with the jugular foramen (glomus jugulare), middle ear (glomus tympanicum), carotid bifurcation, or vagal body. Approximately 35–40% are caused by germline mutations in succinate dehydrogenase (SDH) subunit genes — SDHB, SDHC, and SDHD — with SDHD mutations accounting for the majority of hereditary head and neck paragangliomas due to its paternally imprinted expression. SDHB mutations confer the highest risk of malignant behaviour and metastasis among all SDH subtypes.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Glomus Tumor trials.
Germline SDH gene sequencing (SDHB, SDHC, SDHD, SDHA, SDHAF2) is essential — SDHB mutation status is the strongest predictor of malignant potential and is frequently a stratification criterion in systemic therapy trials.
Functional imaging with 68Ga-DOTATATE PET-CT (somatostatin receptor scintigraphy) is the preferred staging modality and is often required to document extent of disease before trial enrolment.
Catecholamine and metanephrine secretory status must be assessed and, if elevated, managed with alpha-blockade before any surgical or interventional trial procedures to prevent hypertensive crisis.
Patient Resources
Find recruiting Glomus Tumor trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Glomus Tumor. Updated daily.